Antiangiogenic drugs currently used for colorectal cancer: What other pathways can we target to prolong responses?

Drug News and Perspectives

Volumn 20, Issue 5, 2007, Pages 307-313

  Abbadessa, Giovanni ^b,c   Vogiatzi, Paraskevi ^b,d   Rimassa, Lorenza ^e   Claudio, Pier Paolo ^a  

^a MARSHALL UNIVERSITY   (United States)

^b Temple University   (United States)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d UNIVERSITY OF SIENA   (Italy)

^e Dept of Biochemistry and Molecular Biology ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CELECOXIB; CETUXIMAB; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR; ERLOTINIB; FIBROBLAST GROWTH FACTOR; FLUOROURACIL; GEFITINIB; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; PANITUMUMAB; ROFECOXIB; THROMBOCYTE FACTOR 4; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR ALPHA; VASCULOTROPIN; VATALANIB;

ANGIOGENESIS; APOPTOSIS; CANCER CELL; CANCER CHEMOTHERAPY; CELL DEATH; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL RESEARCH; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DRUG APPROVAL; DRUG MECHANISM; HUMAN; HYPOXIA; METASTASIS; MONOTHERAPY; OXYGENATION; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; COLORECTAL NEOPLASMS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34548370717     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2007.20.5.1120218     Document Type: Review

References (70)

1. Jemal, A., Siegel, R., Ward, E. et al. Cancer statistics, 2006. CA Cancer J Clin 2006, 56: 106-30.
2. Abbadessa, G., Santoro, A. and Claudio, P.P. 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO) (June 2-6, Atlanta) 2006. Drugs Fut 2006, 31: 617-23.
3. Folkman, J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971, 285: 1182-6.
4. Brem, H. and Folkman, J. Inhibition of tumor angiogenesis mediated by cartilage. J Exp Med 1975, 141: 427-39.
5. Fidler, I.J. and Ellis, L.M. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994, 79: 185-8.
6. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1: 27-31.
7. Liotta, L.A., Stracke, M.L., Aznavoorian, S.A., Beckner, M.E. and Schiffmann, E. Tumor cell motility. Semin Cancer Biol1991, 2: 111-4.
8. Tonini, T., Rossi, F. and Claudio, P.P. Molecular basis of angiogenesis and cancer. Oncogene 2003, 22: 6549-56.
9. Hanahan, D. and Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86: 353-64.
10. Carmeliet, P. and Jain, R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407: 249-57.
11. Jain, R.K., Duda, D.G., Clark, J.W. and Loeffler, J.S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006, 3: 24-40.
12. Brown, J.M. Tumor microenvironment and the response to anticancer therapy. Cancer Biol Ther 2002, 1: 453-8.
13. Hammond, E.M., Dorie, M.J. and Giaccia, A.J. ATR ATM targets are phosphorylated by ATR in response to hypoxia and ATM in response to reoxygenation. J Biol Chem 2003, 278: 12207-13.
14. Jain, R.K. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005, 307: 58-62.
15. Winkler, F., Kozin, S.V., Tong, R.T. et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004, 6: 553-63.
16. Freiberg, R.A., Hammond, E.M., Dorie, M.J., Welford, S.M. and Giaccia, A.J. DNA damage during reoxygenation elicits a Chk2-dependent checkpoint response. Mol Cell Biol 2006, 26: 1598-609.
17. Yang, W. and Block, E.R. Effect of hypoxia and reoxygenation on the formation and release of reactive oxygen species by porcine pulmonary artery endothelial cells. J Cell Physiol 1995, 164: 414-23.
18. Hirao, A., Kong, Y.Y., Matsuoka, S. et al. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science 200, 287: 1824-7.
19. Lee, J.S., Collins, K.M., Brown, A.L., Lee, C.H. and Chung, J.H. hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response. Nature 2000, 404: 201-4.
20. Rahimi, N. VEGFR-1 and VEGFR-2: Two non-identical twins with a unique physiognomy Front Biosci 2006, 11: 818-29.
21. Gampel, A., Moss, L., Jones, M.C., Brunton, V., Norman, J.C. and Mellor, H. VEGF regulates the mobilisation of VEGFR-2/KDR from an intracellular endothelial storage compartment. Blood 2006.
22. Li, A., Dubey, S.. Varney, M.L., Dave, B.J. and Singh, R.K. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 2003, 170: 3369-76.
23. Nieder, C., Wiedenmann, N., Andratschke, N. and Molls, M. Current status of angiogenesis inhibitors combined with radiation therapy. Cancer Treat Rev 2006, 32: 348-64.
24. Ellis, L.M. Bevacizumab. Nat Rev Drug Discov 2005, Suppl: S8-9.
25. Arora, A. and Scholar, E.M. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005, 315: 971-9.
26. Vincenzi, B., Santini, D., Russo, A. et al. Angiogenesis modifications related with cetuxirnab plus irinotecan as anticancer treatment in advanced colorectal cancer patients. Ann Oncol 2006, 17: 835-41.
27. Ciardiello, F. and Tortora, G. Epidermal growth factor receptor (EGFR) as a target in cancer therapy: Understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer 2003, 39: 1348-54.
28. Wainberg, Z. and Hecht, J.R. A phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer. Clin Colorectal Cancer 2006, 5: 363-7.
29. Chung, K.Y., Shia, J., Kemeny, N.E. et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005, 23: 1803-10.
30. Maxwell, P.H., Wiesener, M.S., Chang, G.W. et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399: 271-5.
31. Vengellur, A., Phillips, J.M., Hogenesch, J.B. and LaPres, J.J. Gene expression profiling of hypoxia signaling in human hepatocellular carcinoma cells. Physiol Genomics 2005, 22: 308-18.
32. Vogelstein, B. and Kinzler, K.W. Cancer genes and the pathways they control. Nat Med 2004, 10: 789-99.
33. Shima, D.T., Deutsch, U. and D'Amore, P.A. Hypoxic induction of vascular endothelial growth factor (VEGF) in human epithelial cells is mediated by increases in mRNA stability. FEBS Lett 1995, 370: 203-8.
34. Semenza, G.L. Hypoxia-inducible factor 1: Control of oxygen homeostasis in health and disease. Pediatr Res 2001, 49: 614-7.
35. Mizukami, Y., Jo, W.S., Duerr, E.M. et al. Induction of interleukin-8 preserves the angiogenic response in HIF-1 alpha-deficient colon cancer cells. Nat Med 2005, 11: 992-7.
36. Holmes, W.E., Lee, J., Kuang, W.J., Rice, G.C. and Wood, W.I. Structure and functional expression of a human interleukin-8 receptor. Science 1991, 253: 1278-80.
37. Yang, S.K., Eckmann, L., Panja, A. and Kagnoff, M.F. Differential and regulated expression of C-X-C, C-C, and C-chemokines by human colon epithelial cells. Gastroenterology 1997, 113: 1214-23.
38. Addison, C.L., Daniel, T.O., Burdick, M.D. et al. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity. J Immunol 2000, 165: 5269-77.
39. Nor, J.E., Christensen, J., Liu, J., Peters, M., Mooney, D.J., Strieter, R.M. and Polverini, P.J. Up-Regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. Cancer Res 2001, 61: 2183-8.
40. Pierce, J.W., Schoenleber, R., Jesmok, G., Best, J., Moore, S.A., Collins, T. and Gerritsen, M.E. Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem 1997, 272: 21096-103.
41. Schreck, R., Rieber, P. and Baeuerle, P.A. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappaB transcription factor and HIV-1. Embo J 1991, 10: 2247-58.
42. Brown, J.R. and DuBois, R.N. COX-2: A molecular target for colorectal cancer prevention. J Clin Oncol 2005, 23: 2840-55.
43. Vallbohmer, D., Zhang, W., Gordon, M. et al. Molecular determinants of cetuximab efficacy. J Clin Oncol 2005, 23: 3536-44.
44. Veronese, M.L. and O'Dwyer, P.J. Monoclonal antibodies in the treatment of colorectal cancer. Eur J Cancer 2004, 40: 1292-301.
45. Leahy, K.M., Ornberg, R.L., Wang, Y., Zweifel, B.S., Koki, A.T. and Masferrer, J.L. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 2002, 62: 625-31.
46. Wirth, L.J., Haddad, R.I., Lindeman, N.I. et al. Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2005, 23: 6976-81.
47. Ali, S., El-Rayes, B.F., Sarkar, F.H. and Philip, P.A. Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy. Mol Cancer Ther 2005, 4: 1943-51.
48. Soumaoro, L.T., Uetake, H., Takagi, Y. et al. Coexpression of VEGF-C and Cox-2 in human colorectal cancer and its association with lymph node metastasis. Dis Colon Rectum 2006, 49: 392-8.
49. Wang, Y.Q., Luk, J.M., Chu, A.C. et al. TNP-470 blockage of VEGF synthesis is dependent on MAPK/COX-2 signaling pathway in PDGF-BB-activated hepatic stellate cells. Biochem Biophys Res Commun 2006, 341: 239-44.
50. Sandler, A.B. Targeting angiogenesis in lung cancer. Semin Oncol 2005, 32: S16-22.
51. Chen, J.J., Yao, P.L., Yuan, A. et al. Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: Its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res 2003, 9: 729-37.
52. Kerbel, R.S. and Kamen, B.A. The antiangiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004, 4: 423-36.
53. Emmenegger, U., Morton, G.C., Francia, G. et al. Low-dose metronomic daily cyclo phosphamide and weekly tirapazamine: A well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia. Cancer Res 2006, 66: 1664-74.
54. Correale, P., Cerretani, D., Remondo, C. et al. A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients. Oncol Rep 2006, 16: 133-40.
55. Klement, G., Huang, P., Mayer, B. et al. Differences in therapeutic indexes of combination metronomic chemotherapy and an and- VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res 2002, 8: 221-32.
56. Browder, T., Butterfield, C.E., Kraling, B.M. et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 200, 60: 1878-86.
57. Bertolini, F., Paul, S., Mancuso, P. et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 2003, 63: 4342-6.
58. Colleoni, M., Rocca, A., Sandri, M.T. et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: Antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002, 13: 73-80.
59. Warburg, O. On respiratory impairment in cancer cells. Science 1956, 10: 269-70.
60. Blagosklonny, M.V. How Avastin potentiates chemotherapeutic drugs: Action and reaction in antiangiogenic therapy. Cancer Biol Ther 2005, 4: 1307-10.
61. Bottaro, D.P. and Liotta, L.A. Cancer: Out of air is not out of action. Nature 2003, 423: 593-5.
62. Semenza, G.L. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol 2000, 35: 71-103.
63. Krishnamachary, B., Berg-Dixon, S., Kelly, B. et al. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res 2003, 63: 1138-43.
64. Tran, J., Master, Z., Yu, J.L., Rak, J., Dumont, D.J. and Kerbel, R.S. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci U S A 2002, 99: 4349-54.
65. Jain, R.K. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 2001, 7: 987-9.
66. Wildiers, H., Guetens, G., De Boeck, G. et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 2003, 88: 1979-86.
67. Tong, R.T., Boucher, Y., Kozin, S.V., Winkler, F., Hicklin, D.J. and Jain, R.K. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res, 2004, 64: 3731-6.
68. Rapisarda, A., Uranchimeg, B., Scudiero, D.A., Selby, M., Sausville, E.A., Shoemaker, R.H. and Melillo, G. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 2002, 62: 4316-24.
69. Drevs, J., Fakler, J., Eisele, S. et al. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. Anticancer Res 2004, 24: 1759-63.
70. Saltz, L. Epidermal growth factor receptor-negative colorectal cancer: Is there truly such an entity? Clin Colorectal Cancer 2005, 5(Suppl 2): S98-100.